REFERENCES

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistic, 2004. CA Cancer J Clin 1994;44:7-26.

2. Lippman ME, Lichter AS, Danforth DN Jr. Diagnosis and Management of Breast Cancer. Philadelphia: WB Saunders Co.; 1988.

3. Henderson IC, Canellos GP. Cancer of the breast: the past decade (first of two parts). N Engl J Med 1980;302:17-30.

4. Bakhtiari A, Haj-Ahmadi M. Five-year assessment of breast cancer at Rajaee Hospital, Baboolsar (1991-1996). Iran J Obstets Gynecol Infertil 2006;9:47-52.

5. Li F, Sturgis EM, Chen X, Zafereo ME, Wei Q, Li G. Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer 2010;116:2350-9.

6. Wang G, Yu D, Tan W, Zhao D, Wu C, Lin D. Genetic polymorphism in chemokine CCL22 and susceptibility to Helicobacter pylori infection-related gastric carcinoma. Cancer 2009;115:2430-7.

7. Kristensen VN, Børresen-Dale AL. SNPs associated with molecular subtypes of breast cancer: On the usefulness of stratified Genome-wide Association Studies (GWAS) in the identification of novel susceptibility loci. Mol Oncol 2008;2:12-5.

8. Kraft P, Haiman CA. GWAS identifies a common breast cancer risk allele among BRCA1 carriers. Nat Genet 2010;42:819-20.

9. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005;23:662-4.

10. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000;12:589-96.

11. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336-47.

12. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.

13. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8.

14. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001;2:145-52.

15. Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, Shi Y, Yao J, Guo Y, Yu D, Tian T, Zhou X, Shen H, Lin D. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008;68:7025-34.

16. Wang L, Li D, Fu Z, Li H, Jiang W, Li D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007;7:173.

17. Kouki T, Sawai Y, Gardine CA, Fisfalen ME, Alegre ML, DeGroot LJ. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000;165:6606-11.

18. Mäurer M, Loserth S, Kolb-Mäurer A, Ponath A, Wiese S, Kruse N, Rieckmann P. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002;54:1-8.

19. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgovişte C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-11.

20. Han SZ, Zhang SH, Li R, Zhang WY, Li Y. The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients. Int J Immunogenet 2006;33:281-7.

21. Anjos SM, Polychronakos C. Functional evaluation of the autoimmunity-associated CTLA4 gene: The effect of the (AT) repeat in the 3'untranslated region (UTR). J Autoimmun 2006;27:105-9.

22. Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, Martins B, Andreia R, Viana JF, Crespo F, Vasconcelos C, Ferreira C, Vicente AM. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 2004;12:620-6.

23. Ghaderi A, Yeganeh F, Kalantari T, Talei AR, Pezeshki AM, Doroudchi M, Dehaghani AS. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004;86:1-7.

24. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 2006;165:114-20.

25. Zheng C, Huang D, Liu L, Björkholm M, Holm G, Yi Q, Sundblad A. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol 2001;112:216-8.

26. Monne M, Piras G, Palmas A, Arru L, Murineddu M, Latte G, Noli A, Gabbas A. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am J Hematol 2004;76:14-8.

27. Mao H, Zhang L, Yang Y, Zuo W, Bi Y, Gao W, Deng B, Sun J, Shao Q, Qu X. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 2010;10:728-36.

28. Shastry BS. SNP alleles in human disease and evolution. J Hum Genet 2002;47:561-6.

29. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993;11:191-212.

30. Brunner-Weinzierl MC, Hoff H, Burmester GR. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: Implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004;6:45-54.

31. Zheng J, Yu X, Jiang L, Xiao M, Bai B, Lu J, Zhou Y. Association between the Cytotoxic T-lymphocyte antigen 4+ 49G > A polymorphism and cancer risk: a meta-analysis. BMC Cancer 2010;10:522.

32. Li D, Zhang Q, Xu F, Fu Z, Yuan W, Li D, Pang D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer risk and clinical features in Han women of northeast China. Mol Cell Biochem 2012;364:283-90.

33. Li H, Fu ZK, Wang LH, Li DL, Wu N, Zhang J, Li DJ. Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms with susceptibility to breast cancer. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2008;24:282-4. (in Chinese)

34. Bi Y, Wei L, Mao HT, Zhang L, Zuo WS. Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors. Zhonghua Zhong Liu Za Zhi 2008;30:749-53. (in Chinese)

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/